Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISIS 5132

Drug Profile

ISIS 5132

Alternative Names: CGP 69846A

Latest Information Update: 16 Sep 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Protein kinase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 16 Sep 2002 Discontinued - Phase-I for Solid tumours in USA (IV-infusion)
  • 16 Sep 2002 Discontinued - Phase-II for Breast cancer in USA (unspecified route)
  • 16 Sep 2002 Discontinued - Phase-II for Colorectal cancer in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top